


Minister of Health



Ministre de la Santé

The Honourable, Honorable A. Anne McAllan

Ottawa, Canada K1A 0K0

DEC 12 2002

Mr. Ron Reinhold
President
Rainbow Investigations
P.O. Box 513
Black Diamond, Alberta T0L 0H0

Dear Mr. Reinhold:

Thank you for your correspondence of September 22, 2002, and enclosures, concerning E.M. Power. I apologize for the delay in responding.

My officials are aware that E.M. Power was involved in clinical trials at the University of Calgary without having received the required authorization under the *Food and Drugs Act* in the summer of 2000. The drug product, E.M. Power, is regulated under the Act as a new drug in Canada. Under the Act, a clinical trial application must be filed with Health Canada. Subsequent to the investigation, the clinical trials were stopped by Health Canada. Should you be aware of continued clinical trial activity, please contact Mr. Dennis Shelly, Manager, Western Operational Centre, Health Products and Food Branch Inspectorate, at (604) 666-3704.

With respect to the Canadian Web site www.truehope.com, it is a violation under the *Food and Drugs Act* to advertise or sell any new drug that has not received a notice of compliance. Subsequent to the investigation previously undertaken, Health Canada was assured by Synergy/TrueHope of the removal of its Canadian Web site. However, it was brought to Health Canada's attention that Synergy/TrueHope did not remove its Web site, and continues to offer E.M. Power for sale. The company has been advised of its obligations, and my officials are furthering their investigation.

Canada


- 2 -

Under Health Canada's *Importation of Human Use Drugs for Personal Use Enforcement Directive*, individuals are allowed to import from a foreign country a 90-day supply of non prescription drugs for their own personal use and not for subsequent sale or distribution. This directive is similar to those exercised by many other countries world-wide.

The activity under investigation regarding E.M. Power is based on violations to advertising, offer for sale, and any possible clinical trials which have not been authorized.

Thank you again for writing.

Yours sincerely,



A. Anne McLellan